Shots:

• The P-III OASIS-2 study involves assessing mirikizumab vs PBO & Cosentyx (secukinumab) in 1-465 patients with mod. to sev. PsO. The patients were randomized in a (4:4:4:1) ratio to one of the following induction and maintenance period treatments: mirikizumab (250mg) @ 0- 4- 8- 12wks. followed by 250 & 125mg- q8w starting @16wks; 300mg secukinumab @ 0- 1- 2- 3- 4wks. followed by 300mg- q4w starting @4wks.; PBO @ 0- 4- 8- 12 wks. followed by 250mg mirikizumab q4w starting @16wks. through 32wks. followed by q8w thereafter
• Results: @16wks. sPGA(0-1) (79.7% vs 6.3% & 76.3%)- PASI 90 (74.4% vs 6.3% & 72.8%); PASI 100 (37.7% vs 1.8% & 36.6%). In general- the study resulted in meeting its 1EPs and all key 2EPs vs PBO @16wks. and all key 2EPs vs Cosentyx (secukinumab) @16wks. (non-inferiority) and @52wks. (superiority)
• Mirikizumab is an IgG4 mAb binding p19 subunit of IL-23 and being evaluated for immune diseases- including psoriasis- UC and CD

  Ref: Eli Lilly | Image: Eli Lilly